Latest Press Releases
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
IRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc. today announced that Phase 3 monotherapy data from the BOND-003 clinical trial evaluating the efficacy and safety of cretostimogene grenadenorepvec in patients with high-risk NonMuscle Invasive Bladder Cancer (NMIBC)...
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023
IRVINE, Calif. (BUSINESSWIRE)--CG Oncology, Inc. announced today that interim Phase 3 monotherapy data from the BOND-003 study will be presented as a late-breaking abstract at the upcoming 24th Annual Meeting of the Society of Urologic Oncology (SUO), held November...
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
Company appoints Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer With decades of proven experience, they bring leadership to successfully lead...
Upcoming Conferences
24th Annual Meeting of the SUO
2023 Annual Meeting
Nov 28 – Dec 1, 2023
Washington DC
contact: information@cgoncology.com
CG Oncology in the News
ENDPOINTS NEWS
August 2, 2023
CG Oncology reels in $105M crossover for potential late 2024 bladder cancer drug filing
FIERCE BIOTECH
August 2, 2023
CG Oncology brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial
